ProPhase Labs Financials

PRPH Stock  USD 0.77  0.01  1.28%   
Based on the key indicators related to ProPhase Labs' liquidity, profitability, solvency, and operating efficiency, ProPhase Labs may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. As of now, ProPhase Labs' Net Debt is increasing as compared to previous years. The ProPhase Labs' current Accounts Payable is estimated to increase to about 9.9 M, while Total Stockholder Equity is projected to decrease to under 25.1 M. Key indicators impacting ProPhase Labs' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.180.2077
Fairly Down
Pretty Stable
Current Ratio3.832.2815
Way Up
Very volatile
The essential information of the day-to-day investment outlook for ProPhase Labs includes many different criteria found on its balance sheet. An individual investor should monitor ProPhase Labs' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in ProPhase Labs.

Net Income

(15.94 Million)

  
Understanding current and past ProPhase Labs Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ProPhase Labs' financial statements are interrelated, with each one affecting the others. For example, an increase in ProPhase Labs' assets may result in an increase in income on the income statement.

ProPhase Labs Stock Summary

ProPhase Labs competes with Star Equity, Enzo Biochem, Neuronetics, Intelligent Bio, and Biodesix. ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS74345W1080
CUSIP74345W108 74838L304
LocationPennsylvania; U.S.A
Business Address711 Stewart Avenue,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.prophaselabs.com
Phone215 345 0919
CurrencyUSD - US Dollar

ProPhase Labs Key Financial Ratios

ProPhase Labs Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets12.3M31.4M89.3M87.6M91.9M96.5M
Net Debt(434K)7.9M6.5M(2.1M)19.2M20.2M
Retained Earnings(1.5M)(3.6M)2.6M11.8M(5.0M)(4.8M)
Accounts Payable432K3.8M7.0M5.9M9.4M9.9M
Cash434K6.8M8.4M9.1M2.1M2.0M
Net Receivables6.8M3.2M37.7M37.1M36.3M38.1M
Inventory1.5M3.0M4.6M4.0M3.8M2.9M
Other Current Assets304K2.5M1.7M2.4M2.7M4.2M
Total Liab1.0M20.8M30.7M24.0M42.5M44.7M
Total Current Assets9.9M15.9M61.3M60.8M47.6M27.5M
Other Current Liab397K1.7M3.8M2.9M3.0M3.3M
Net Tangible Assets16.5M11.2M8.4M42.1M48.4M50.8M
Capital Surpluse58.0M59.5M60.2M61.7M70.9M58.8M

ProPhase Labs Key Income Statement Accounts

201920202021202220232024 (projected)
Total Revenue9.9M14.5M79.0M122.6M44.4M35.5M
Gross Profit2.6M4.6M32.8M70.7M16.2M14.0M
Operating Income(3.2M)(4.0M)9.8M23.6M(21.6M)(20.5M)
Ebit(3.2M)(2.0M)6.5M23.7M(21.5M)(20.4M)
Ebitda(2.8M)(1.5M)11.4M28.7M(14.8M)(14.1M)
Net Income(3.0M)(2.4M)6.3M18.5M(16.8M)(15.9M)
Income Tax Expense(93K)94K(968K)4.4M(6.0M)(5.7M)
Cost Of Revenue7.3M9.9M46.2M52.0M28.1M16.8M
Income Before Tax(3.1M)(2.3M)5.3M22.9M(22.8M)(21.7M)
Research Development332K633K520K652K1.4M1.4M
Interest Income133K62K642K153K69K65.6K
Net Interest Income133K(233K)(506K)(611K)(841K)(799.0K)

ProPhase Labs Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash(1.1M)6.4M1.8M451K(7.0M)(6.6M)
Free Cash Flow(1.1M)(4.3M)(17.9M)24.6M(14.5M)(13.8M)
Other Non Cash Items40K118K(311K)5.5M896K940.8K
Capital Expenditures228K1.7M4.2M3.9M3.2M3.3M
Net Income(3.1M)(2.1M)6.3M18.5M(16.8M)(15.9M)
End Period Cash Flow434K6.8M8.7M9.1M2.1M2.0M
Change To Inventory444K(1.5M)(1.7M)702K135K141.8K
Depreciation398K458K3.6M5.1M6.7M7.0M
Change Receivables3.8M(1.0M)936K(1.0M)(1.2M)(1.1M)
Dividends Paid5.8M2.9M4.5M9.4M193K183.4K
Change To Netincome796K(318K)11.2M9.4M10.8M11.3M
Investments5.8M(720K)(19.7M)(2.1M)(5.1M)(5.4M)

ProPhase Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ProPhase Labs's current stock value. Our valuation model uses many indicators to compare ProPhase Labs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ProPhase Labs competition to find correlations between indicators driving ProPhase Labs's intrinsic value. More Info.
ProPhase Labs is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, ProPhase Labs' Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ProPhase Labs' earnings, one of the primary drivers of an investment's value.

ProPhase Labs Systematic Risk

ProPhase Labs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ProPhase Labs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on ProPhase Labs correlated with the market. If Beta is less than 0 ProPhase Labs generally moves in the opposite direction as compared to the market. If ProPhase Labs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ProPhase Labs is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ProPhase Labs is generally in the same direction as the market. If Beta > 1 ProPhase Labs moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ProPhase Labs Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ProPhase Labs' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ProPhase Labs growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0265

As of now, ProPhase Labs' Price Earnings To Growth Ratio is increasing as compared to previous years.

ProPhase Labs November 22, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of ProPhase Labs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ProPhase Labs. We use our internally-developed statistical techniques to arrive at the intrinsic value of ProPhase Labs based on widely used predictive technical indicators. In general, we focus on analyzing ProPhase Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ProPhase Labs's daily price indicators and compare them against related drivers.

Complementary Tools for ProPhase Stock analysis

When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.